KRAS and neoplasm: It is also worth commenting that even with the achievement of synergy between irinotecan chemo-immunotherapy and anti-PD1 administration, orthotopic KRAS tumors often present with heterogeneous immune landscapes, requiring additional therapeutic intervention, including dealing with a dysplastic stroma and an immune-suppressed tumor immune microenvironment (TIME) [4].